ArticleDiabetes, obesity & metabolism2026
Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsThe association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP-1RA use and the incidence of bowel obstruction/ileus subtypes across different subgroups of individuals.
methodsUsing the commercially available Japanese administrative claims DeSC database, we identified individuals aged ≥ 18 years with type 2 diabetes who newly initiated either GLP-1RAs or sodium-glucose cotransporter 2 inhibitors (SGLT2is) between April 2016 and February 2024. An active-comparator new-user design was adopted, designating GLP-1RA users as the exposure group and SGLT2i users as the control group. The primary outcome was bowel obstruction/ileus requiring tube decompression or surgery within 1 year. Secondary outcomes included specified small bowel obstruction, small bowel obstruction requiring surgery, paralytic ileus and colonic volvulus. Inverse probability weighting with propensity scores was used to adjust for confounding. Adjusted cumulative incidence was estimated using Kaplan-Meier methods; hazard ratios were estimated using Cox regression.
resultsAmong 298 124 eligible individuals, 25 779 and 272 345 were classified into the GLP-1RA and SGLT2i groups, respectively. The adjusted 1-year incidence proportion of the primary outcome did not significantly differ between groups (0.14% vs. 0.17%; difference -0.03%, 95% confidence interval (CI), -0.10% to 0.04%; hazard ratio 0.80, 95% CI, 0.52-1.24). No significant between-group differences were observed for the secondary outcomes.
conclusionsGLP-1RA initiation in individuals with type 2 diabetes was not associated with an increased risk of bowel obstruction/ileus compared with SGLT2i initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.